ArticleOphthalmology science2026
Unfolding the Pitchfork Sign in Type 2 Choroidal Neovascularization: A Longitudinal Analysis and 3-Dimensional Reconstructions.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To longitudinally characterize and redefine the structural basis and clinical significance of the pitchfork sign in type 2 choroidal neovascularization (CNV) using multimodal imaging with 3-dimensional confirmation. Design: Retrospective observational study. Subjects: Thirty-nine eyes with treatment-naive type 2 CNV showing a pitchfork sign on spectral-domain OCT. Methods: Outer retinal changes were graded, focusing on splitting at the ellipsoid zone (EZ) and infolding of the external limiting membrane (ELM). Quantitative measures included projection number, maximal fold height, subretinal fluid (SRF) height, subretinal hyperreflective material (SHRM) height, and posttreatment pigment epithelial detachment (PED) height; correlations with best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) were assessed. Three-dimensional reconstructions of the outer retina were generated to verify the spatial configuration of folds. Main Outcome Measures: Structural characterization of the retinal layer involved in the pitchfork sign; quantitative morphologic parameters (projection number and maximal fold height); their correlation with exudative and anatomical features (SRF, SHRM, PED height); and association with BCVA. Results: The pitchfork sign occurred in idiopathic (69%), inflammatory (23%), and myopic (8%) CNV, indicating it is not disease-specific. Imaging revealed a reproducible mechanical sequence: elevation of the outer retina by type 2 CNV; cleavage at the EZ with formation of a new fluid-filled split between the EZ and ELM; centrifugal buckling and infolding from the lesion margin toward the CNV core; and, in some eyes, transient partially enclosed "mushroom-shaped" closed folds that trapped fluid. These folds ultimately collapsed into sharply angulated vertical hyperreflective lines-the pitchfork configuration. Three-dimensional reconstructions confirmed that the apparent "tines" are radially arranged outer retinal folds anchored to the neovascular complex. Quantitatively, fold number correlated with SRF height (r = 0.40, Conclusions: The pitchfork sign in type 2 CNV reflects transient, mechanically induced folding and splitting of the outer retina overlying subretinal neovascular tissue, rather than an inflammatory biomarker. Greater retinal deformation at presentation was associated with worse presenting vision and with a higher fibrovascular PED after treatment. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.